Holen Sie sich die Stockscreener-App
3.6401
4.00%
0.1401
Schlusskurs vom Vortag:
$3.50
Offen:
$3.5681
24-Stunden-Volumen:
1,465
Relative Volume:
0.11
Marktkapitalisierung:
$372.13M
Einnahmen:
$16.82M
Nettoeinkommen (Verlust:
$-112.19M
KGV:
-1.6409
EPS:
-2.2183
Netto-Cashflow:
$-91.84M
1W Leistung:
-6.42%
1M Leistung:
+17.42%
6M Leistung:
+32.37%
1J Leistung:
+13.75%
1-Tages-Spanne:
$3.5681
$3.6779
1-Wochen-Bereich:
$3.50
$3.89
52-Wochen-Spanne:
$1.53
$4.05
Inventiva Adr Stock (IVA) Company Profile
Vergleichen Sie IVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.6511 | 372.13M | 16.82M | -112.19M | -91.84M | -2.2183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.22 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.21 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.41 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.94 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.50 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-21 | Eingeleitet | TD Cowen | Buy |
| 2024-11-12 | Eingeleitet | UBS | Neutral |
| 2023-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-19 | Hochstufung | Societe Generale | Sell → Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2022-11-15 | Herabstufung | Societe Generale | Buy → Sell |
| 2021-03-08 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Eingeleitet | ROTH Capital | Buy |
| 2020-08-04 | Eingeleitet | Guggenheim | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Inventiva Adr Aktie (IVA) Neueste Nachrichten
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright - TipRanks
Stifel maintains Buy on Inventiva shares with $17 target - Investing.com
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée - GlobeNewswire Inc.
Inventiva SA ADR Reports 2024 Financial Results and Strategic Updates - TipRanks
Inventiva earnings missed by $0.03, revenue topped estimates - Investing.com
Top 10 Best Indian Companies In Smart Grids Solutions 2025 - Inventiva
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - inventiva.co.in
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Nasdaq
NOTA, No Votes and Unopposed Nominations: The Grey Areas of the Indian Election Process Explained - inventiva.co.in
symbol__ Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
Top 10 Best Handicraft Companies In USA 2023 - inventiva.co.in
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Inventiva SaAdr Share Price Today (NASDAQ: IVA)Inventiva SaAdr Stock Price Live Quote - INDmoney
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Finanzdaten der Inventiva Adr-Aktie (IVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):